Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Targeting DNA damage response and repair excluding PARP for triple negative breast cancer

Share :

IMPAKT 2012

3 - 5 May 2012
Published: 17 May 2012
Views: 3934
Rating:
Save
Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden

Prof Helleday talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about novel therapies for triple negative breast cancer including the use of 6-mercaptopurine, previously not used in this group of patients.

The plan is to tackle cells which have been resistant to cisplatin or PARP inhibitors; Prof Helleday discusses studies underway.

 

Filming Supported by Amgen

 

 

Related Videos

Targeted therapies associated with increased risk for and incidence of...
Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024
ESMO 2024: Highlights and analysis
Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024
Four chemo cycles given with durvalumab and tremelimumab optimise response and...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
LUMINANCE: Results support use of durvalumab and platinum-etoposide for...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
Management of HER2 positive metastatic breast cancer treatment algorithm
Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA
Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )
31 Jan 2023
Post neoadjuvant management in BRCA mutant breast cancer patients
Prof Banu Arun - MD Anderson Cancer Center, Houston, USA
Post neoadjuvant management in BRCA mutant breast cancer patients ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )
31 Jan 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation